Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

By LabMedica International staff writers
Posted on 21 Apr 2026

Early detection across multiple cancers remains a major unmet need in population screening. More...

Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages. A new urine-based multi-cancer early detection test has received U.S. Food and Drug Administration (FDA) Breakthrough Device Designation, recognizing its potential to enable earlier detection from a single urine sample.

TOBY, Inc.’s urine-based Multi-Cancer Early Detection (MCED) test is the first urine-based MCED technology to receive FDA Breakthrough Device Designation. The platform is designed to detect more than ten cancers from a single non-invasive sample, representing over 60% of global cancer cases. The designation builds on the U.S. Food and Drug Administration’s previous Breakthrough Device Designation granted to the company for its urine-based bladder cancer test. Founded in 2023, the company develops non-invasive cancer screening technologies.

The MCED platform analyzes volatile organic compounds (VOCs) in urine using spectroscopy and machine learning to identify cancer‑associated molecular patterns. The test requires only one urine sample and offers an alternative to blood-based screening approaches. The technology is described as supporting scalable population screening for multi-cancer detection.

Within the U.S. FDA program, Breakthrough Device Designation is intended to expedite development and review of medical devices that may provide more effective diagnosis or treatment of serious or life‑threatening diseases. The designation supports continued progress toward expanded clinical studies, future regulatory submissions, and reimbursement. The company indicates it will work closely with the agency to establish the evidence required for broad clinical adoption.

"This Breakthrough Device Designation marks a defining moment for TOBY and for the future of cancer screening. It reinforces our conviction that urine-based, non-invasive detection can fundamentally change how and when cancer is identified, not just by improving the patient experience, but by enabling screening to happen earlier and at scale," said Matthew Laskowski, Chief Executive Officer of TOBY. 

"We believe the next generation of cancer detection will be built around approaches that are simple, accessible, and designed for broad population use, rather than constrained by the limitations of existing modalities, and our platform is engineered with that vision in mind, supporting multi-cancer detection from a single sample. Working closely with the FDA, we are now positioned to accelerate clinical validation and generate the evidence required to bring a more scalable, widely accessible approach to early cancer detection into routine care."

Related Links
TOBY


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.